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Studies of tumor growth and metastasis in small animal 
models have benefi ted greatly from the expanded availabil-
ity of optical imaging techniques that specifi cally detect tu-
mor tissue in live animals [1] and [2]. A major advantage of 
optical imaging is the cost-effective accessibility of the req-
uisite instrumentation. Several promising methods use mo-
lecular approaches to enhance the specifi city of optical de-
tection. Frequently, chosen techniques include measurement 
of bioluminescence, in which tumor cell lines bearing a lu-
ciferase reporter gene are detected by systemic delivery of a 
luminescent substrate, and gene-encoded fl uorescence of tu-
mor cell lines expressing green or red fl uorescent proteins [3] 
and [4]. Although both tumor detection methods are power-
ful and sensitive, their major limitation is a requirement for 
specifi c cell lines. An alternative approach is the exploitation 
of high-affi nity receptor–ligand interactions to target molec-
ular features of the tumor cell with coupled fl uorophores.
Targeting agents that have been used successfully for op-
tical noninvasive detection of tumor xenografts in mice in-
clude monoclonal antibodies [5] and [6], small polypeptide 
growth factors [7] and [8], and peptide analogues of extra-
cellular ligands such as endostatin [9] and somatostatin [10]. 
The most effective coupled fl uorophores are those with fl uo-
rescence emission maxima in the near-infrared (NIR) range 
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Abstract: Receptor targeting is an effective method of enhancing fl uorescence signal in tumors for optical imaging. We previ-
ously used epidermal growth factor (EGF) conjugated to IRDye 800CW to detect and track orthotopic prostate tumors in mice. In 
this study, our goal was to identify a reliable assay for targeting agent integrity in vitro that correlated with signal strength in vivo. 
Binding of IRDye 800CW EGF to intact A431 human epidermoid carcinoma cells was quantifi ed in a microplate assay. Specifi c-
ity was confi rmed by competition with unlabeled EGF or monoclonal antibody blocking. Biological activity of intact and dam-
aged targeting agents relative to unlabeled EGF was determined by binding and stimulation of extracellular signal-regulated ki-
nase (ERK) phosphorylation. Both assays indicated a reduction of up to 60% of the fl uorescence intensity with damaged agents. 
Using a research prototype imaging system optimized for IRDye 800CW detection, we compared the effi cacy of intact and dam-
aged targeting agents for imaging subcutaneous tumors in mice. In live animal images and in sections of the excised tumors, dam-
aged targeting agents consistently yielded diminished fl uorescence signals corresponding to the reduction observed in microplate 
assays. This is the fi rst study to directly correlate targeting agent signal strength in whole cell binding, In-Cell Western, and in 
vivo near-infrared imaging. 
Keywords: EGF receptor, IRDye 800CW EGF, In-Cell Western assay, Binding affi nity, Noninvasive, Whole animal imaging 
Abbreviations: NIR, near-infrared; RGD, Arg-Gly-Asp; EGF, epidermal growth factor; ERK, extracellular signal-regulated ki-
nase; ATCC, American Type Culture Collection; DMEM, Dulbecco’s modifi ed Eagle’s medium; MEM, minimal essential me-
dium; PBS, phosphate-buffered saline; FPLC, fast protein liquid chromatography; TEAA, triethylammonium acetate; CCD, 
charge-coupled device; SNR, signal-to-noise ratio; ROI, region of interest; FITC, fl uorescein isothiocyanate.
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of 780 to 850 nm. Due to low-absorbance spectra of bodily 
fl uids and tissues, imaging in the NIR offers the advantages 
of relatively deep tissue penetration and low autofl uores-
cence [11] and [12]. Examples include targeting of the inte-
grin αvβ3 using variations of Arg-Gly-Asp (RGD) peptides 
linked to Cy5.5 [13], [14], [15], and [16], Alexa Fluor 680 
[13], and IRDye 800CW [16]. Recently, epidermal growth 
factor (EGF) labeled with Cy5.5 was used to quantify ther-
apeutic effi cacy of anti-EGF receptor antibodies for treating 
mammary carcinoma in mice [8].
To optimize receptor-targeted signal strength in NIR 
optical imaging, a detailed understanding of the targeting 
mechanism and fl uorophore function is critical. The EGF 
receptor is a potential biomarker for numerous preclini-
cal models of human cancer because its expression is el-
evated an order of magnitude or more relative to normal 
cells in cancers of the breast [17], prostate [18], lung [19], 
ovary [20], and brain [21]. Furthermore, its signaling func-
tions are well characterized and accessible to convenient 
high-throughput in vitro validation assays to ensure that 
bioactivity of the ligand is maintained despite chemical 
coupling. For example, EGF binds to a cell surface trans-
membrane receptor tyrosine kinase, and this induces di-
merization of the receptors, triggering a phosphorylation 
cascade through numerous extracellular-regulated kinases 
[22]. Because antibodies are available to specifi cally quan-
tify the phosphorylated form of several kinases, activity of 
EGF may be verifi ed directly by receptor binding and indi-
rectly by stimulated kinase activity.
We previously conjugated IRDye 800CW to EGF to 
track longitudinal growth of orthotopic prostate tumors in 
mice [23] and found that the conjugate was a sensitive tu-
mor targeting agent with excellent tissue penetration. We 
hypothesized that an aspect of the normal function of EGF 
contributing to the strong signal obtained from this agent 
could be receptor-mediated endocytosis of the ligand–re-
ceptor complex. This would imply that initial high-affi n-
ity binding of the targeting agent is essential for maximal 
fl uorescence signal strength in animals. Thus, animal num-
bers could be minimized in imaging experiments if subop-
timal conjugate binding in vitro was found to correlate with 
reduced tumor targeting effi cacy in vivo. Furthermore, it 
would be very powerful to have a straightforward in vitro 
assay that could directly predict relative effi ciencies of two 
different drugs or ligands with the same in vivo target. In 
this study, we used IRDye 800CW EGF to target A431 hu-
man epidermoid carcinoma cells in vitro and in vivo. Spe-
cifi cally, we compared whole cell binding, extracellular 
signal-regulated kinase (ERK) phosphorylation, and sub-
cutaneous tumor targeting of optimal and damaged conju-
gates. Our characterization confi rms that poor quality of a 
receptor targeting agent can be detected by measuring in vi-
tro binding equilibria and that reduced bioactivity is detri-
mental to imaging sensitivity.
Materials and methods
Cell culture, materials, and reagents
A431 human epithelial squamous carcinoma cells were pur-
chased from American Type Culture Collection (ATCC, 
Manassas, VA, USA) and maintained in Dulbecco’s modi-
fi ed Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum. PC3M-LN4 human prostate adenocarcinoma 
cells were kindly provided by Isaiah J. Fidler (M.D. Ander-
son Cancer Center, Houston, TX, USA) and maintained in 
minimal essential medium (MEM) containing 10% fetal bo-
vine serum, sodium pyruvate, and nonessential amino ac-
ids. A purifi ed mouse diet (AIN-93M) was obtained from 
Harlan Teklad (Madison, WI, USA). Monoclonal antibody 
C225 (Cetuximab, ImClone Systems) was graciously pro-
vided by Chun Li (M. D. Anderson Cancer Center). TO-
PRO-3 was obtained from Molecular Probes (Eugene, OR, 
USA). Antibodies specifi c for β-tubulin (H-235) and p-
ERK (E-4) were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). The IRDye 800CW EGF targeting 
agent, as well as the Odyssey Infrared Imaging and Aerius 
Automated Infrared Imaging Systems, were provided by LI-
COR Biosciences (Lincoln, NE, USA).
Characterization of IRDye 800CW EGF binding specifi city 
in vitro
The binding specifi city of the IRDye 800CW EGF com-
pound was evaluated on A431 and PC3M-LN4 cells by 
an In-Cell Western assay [23] and [24]. Briefl y, cells were 
grown to approximately 90% confl uency in a microti-
ter plate (Nunc, Roberts, WI, USA) and starved for 2 h 
in serum-free media. For binding assays, starvation me-
dia were replaced with media containing increasing con-
centrations of IRDye 800CW only (0.002–3.3 μM) or 
IRDye 800CW EGF (0.01–70 nM). Specifi city of the la-
beled compound was evaluated by competition assays in 
which starvation media were replaced with media contain-
ing unlabeled EGF (in increasing concentrations from 0.01 
to 2.14 μM) + IRDye 800CW EGF (70 nM) or C225 (0.5–
200 μg/ml) + IRDye 800CW EGF (70 nM). Cells were in-
cubated at room temperature (25 °C) for 2 min and fi xed 
with 4% formaldehyde solution for 20 min. Four washes 
in 1 × phosphate-buffered saline (PBS) + 0.1% Triton X-
100 were done to remove unbound dye and permeabi-
lize the cells. The plates were blocked in Odyssey Block-
ing Buffer for 1.5 h and then incubated with TO-PRO-3 
(1:5000) for normalization of cell number using the 700-
nm channel. Washing steps were repeated, and the plate 
was scanned on Aerius. Quantifi cations were normalized 
by ratiometric analysis of the 700-nm values applied to the 
800-nm values.
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Preparation of targeting agents
High-quality targeting agents were prepared by standard fast 
protein liquid chromatography (FPLC) methods. All separa-
tions were performed on an Agilent 1100 series HPLC sys-
tem (Agilent Technologies, Santa Clara, CA, USA). Sam-
ple detection employed a diode array detector set at 260 and 
780 nm, and purifi cations were carried out at 5 °C. Stan-
dard FPLC conditions were achieved with this instrument 
using an isocratic method suitable for size exclusion chro-
matography. Following conjugation, the coupling mix-
ture was applied to a 35 × 250-mm Omnifi t column (West-
ern Analytical Products, Wildomar, CA, USA) packed with 
Superdex 30 gel fi ltration media (GE Healthcare/Amer-
sham Biosciences, Piscataway, NJ, USA). This column was 
equilibrated and eluted at 0.5 ml/min (6 bar pressure) with 
isocratic 1 × PBS (pH 7.4). The eluted material was fi lter 
sterilized by passage through a 0.2-μm syringe fi lter into a 
sterile container. Absorbance at 280 nm was used to calcu-
late EGF concentration from the published molar extinction 
coeffi cient. Dual wavelength absorbances were used to de-
termine the dye/protein ratio, which was maintained consis-
tently across all coupling reactions. Dual wavelength absor-
bance traces from size exclusion chromatography were also 
used to determine the relative amounts of coupled and unre-
acted dye in all preparations.
Poor-quality targeting agents were prepared by subject-
ing unlabeled EGF or IRDye 800CW EGF to HPLC puri-
fi cation, which is detrimental to protein activity because 
of the harsh denaturing solvent conditions [25]. A reverse-
phase C18 Zorbax column (250 × 9.6 mm, 300 Å pore size, 
5 μm particle size) was used. Solvents included aqueous 50 
mM triethylammonium acetate (TEAA, pH 5.9) (A) and 
acetonitrile (B) in a gradient of 20% B to 31% B in 15 min. 
The purifi cation was performed at a fl ow rate of 4.7 ml/
min (100 bar pressure). Sample was protected from light, 
dried overnight under vacuum, reconstituted in 1 × PBS, 
and applied to a cation (Na+ resin) exchange column equil-
ibrated with 1 × PBS. Following elution from the column 
with 1 × PBS, the sample was lyophilized. Protein concen-
tration, dye/protein ratio, and unreacted dye quantity were 
measured as above.
Quantifi cation of downstream signaling by IRDye 800CW 
EGF
The ability of the targeting agent to stimulate ERK phos-
phorylation in A431 cells was compared with that of unla-
beled EGF. Cells at 90% confl uence in a 96-well plate were 
serum starved for 2 h. Starvation media were replaced with 
stimulation media containing 0.03 to 14 nM IRDye 800CW 
EGF (FPLC), IRDye 800CW EGF (HPLC), unlabeled EGF 
(FPLC), or unlabeled EGF (HPLC). Cells were incubated 
for 2 min at room temperature followed by fi xation and per-
meabilization as above. An initial scan on Aerius was done 
to obtain the level of signal from the conjugated EGF bound 
to receptors. Then plates were blocked for 1.5 h in Odyssey 
Blocking Buffer followed by incubation with anti-β-tubu-
lin (1:100) and anti-p-ERK (1:100) for 1.5 h at room tem-
perature. Plates were washed four times in 1 × PBS + 0.1% 
Tween 20 prior to incubation with IRDye 800CW goat anti-
rabbit (1:800) and IRDye 680 goat anti-mouse (1:200) anti-
body conjugates for 1 h. Cells were washed again, and the 
plate was scanned on the Aerius. The fi nal ratiometric anal-
ysis was adjusted for the initial binding signal, and p-ERK 
signal was normalized to β-tubulin.
Subcutaneous injections
Male NOD/SCID mice (Jackson Laboratory, Bar Harbor, 
ME, USA) and athymic Nu/Nu mice (Charles River, Wilm-
ington, MA, USA) used in these experiments were main-
tained under the supervision and guidelines of the Univer-
sity of Nebraska–Lincoln Institutional Animal Care and Use 
Committee. PC3M-LN4 cells were trypsinized, washed, and 
resuspended at 5 × 106 cells/ml in serum-free MEM [26]. 
Each NOD/SCID mouse was injected subcutaneously in the 
fl ank with 100 μl of cell suspension (0.5 × 106 cells) using a 
1-ml insulin syringe. Tumors reached approximately 0.5 cm 
in size at 4 weeks. A431 cells were trypsinized, washed, and 
resuspended at 2 × 107 cells/ml in serum-free medium for 
subcutaneous injections in the fl ank (2 × 106 cells) of male 
athymic Nu/Nu mice. Animals were carried for approxi-
mately 2 weeks until tumors reached roughly 0.5 cm in size.
In vivo imaging of IRDye 800CW EGF
NIR fl uorescence imaging in live animals was performed 
with a research prototype LI-COR Biosciences small ani-
mal imager. The LI-COR instrument is a light tight chamber 
equipped with a cooled charge-coupled device (CCD) cam-
era, area illumination via diode lasers, and a selection of ex-
citation and detection optical fl uorescent fi lters tuned specifi -
cally for IRDye 800CW. Images were acquired and analyzed 
with Wasabi software (Hamamatsu Photonics, Hamamatsu 
City, Japan) or Adobe Photoshop (Adobe Systems, San Jose, 
CA, USA). NOD/SCID mice were shaved prior to image 
collection. All mice were anesthetized with 2% isofl urane 
throughout procedures.
To establish initial conditions, IRDye 800CW EGF 
(1 nmol) was injected via the tail vein into a tumor-negative 
mouse of each strain and evaluated for systemic clearance by 
NIR imaging at intervals of 1 to 24 h over a period of 3 days, 
after which time more than 90% of the signal had cleared. 
Then mice bearing subcutaneous PC3M-LN4 or A431 tu-
mors (diameter ~0.5 cm) were injected with IRDye 800CW 
EGF (1 nmol) and evaluated for tumor-specifi c retention of 
the agent by NIR imaging at 24-h intervals for up to 8 days. 
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Signal-to-noise ratios (SNRs) calculated as described below 
were used to determine an optimal time point of 72 to 96 h 
for imaging tumors. Subsequently, an additional eight athy-
mic mice with A431 tumors were injected to compare signal 
strength of the targeting agents prepared by different meth-
ods. One mouse was injected with 0.9% saline, one mouse 
received unconjugated IRDye 800CW, two mice were given 
IRDye 800CW EGF (1 nmol) from sources A and B purifi ed 
by FPLC, and four mice were injected with HPLC-damaged 
IRDye 800CW EGF (1 nmol) purifi ed by HPLC. Animals 
were imaged 3 days postinjection and euthanized. Tumors 
were excised, weighed, measured, and paraffi n embedded 
for section scan analysis on Odyssey.
Statistical analysis
Images for each mouse were normalized using the same in-
tensity scale with a common minimum and maximum value. 
SNR was calculated using the following formula:
Regions of interest (ROIs) with identical areas were used 
for both tumor and background. ROIs were quantifi ed for to-
tal pixel and mean pixel values. The standard deviation of 
mean backgrounds was calculated using three to fi ve ROIs. 
This calculation yields the number of standard deviations 
over background represented by the suspect tumor/signal. 
Due to tumor size differences between the animals receiving 
quality targeting agents, tumor signal minus background sig-
nal of similar-size ROI was then corrected for area (pixels). 
The percentage difference from FPLC-purifi ed agent was 
determined for HPLC-purifi ed agents.
Tissue section analysis
After fi nal imaging (day 3 or 4 postinjection), animals were 
sacrifi ced. Tumors were excised, scanned on Odyssey, 
weighed, measured, and preserved in Z-fi x (Anatech, Battle 
Creek, MI, USA), followed by paraffi n embedding and tissue 
sectioning. Sections (5 μm thickness) were scanned in both 
the 700-nm channel, for tissue autofl uorescence, and the 800-
nm channel, for the targeted IRDye 800CW EGF fl uores-
cence signal using Odyssey. The area-weighted fl uorescence 
signal from the 800-nm channel was used to compare target-
ing agent specifi cities among experimental conditions.
Results and discussion
In vitro specifi city of IRDye 800CW EGF for tumor cell 
lines
Effective use of whole animal NIR optical imaging for sen-
sitive detection of tumor tissue requires highly specifi c bio-
markers that can be labeled to illuminate tumor cells within 
live mice. Maximal emission of IRDye 800CW is 789 nm, 
so it falls in an optimal region of the spectrum to obtain su-
perior signal strength. We previously coupled EGF to IRDye 
800CW and found this targeting agent to be highly sensi-
tive and specifi c due to its strong signal [23]. Our goal in the 
current study was to determine an aspect of EGF biological 
function quantifi able in vitro that refl ects maximal tumor tar-
geting potential.
We fi rst characterized binding of the targeting agent to 
A431 cells by a microplate NIR fl uorescence assay as we 
had done previously for PC3M-LN4 human prostate tumor 
cells [23]. Confl uent monolayer cultures of A431 cells were 
established in 96-well plates and treated with increasing 
concentrations of IRDye 800CW EGF to establish a dose–
response curve for binding of the targeting agent to EGF re-
ceptors on the cells. Fluorescence signal became signifi cant 
at 1 nM concentrations and increased exponentially in a con-
centration-dependent fashion (Figure 1A). To verify recep-
tor targeting, we performed the same measurements with 
unconjugated dye, showing negligible increases in fl uores-
cence over a similar concentration course (Figure 1A, cir-
cles). The specifi city of the conjugate for the EGF receptor 
on the cells was evaluated by competitions with unlabeled 
EGF (Figure 1B) and with C225, a monoclonal antibody that 
blocks ligand binding by the EGF receptor [27] (Figure 1C). 
Unlabeled EGF reduced fl uorescence in a concentration-de-
pendent manner with an IC50 of approximately 0.1 μM. The 
antibody competition was also dose dependent with an IC50 
of approximately 10 μg/ml. These results are comparable to 
those obtained with prostate tumor cells. Importantly, satu-
ration of binding to whole cells occurred above 0.1 μM. The 
value was approximately 0.16 μM for PC3M-LN4 cells, 
showing a half-maximal binding constant of approximately 
70 to 80 nM, in good agreement with the inhibition constant 
for unlabeled EGF. Thus, coupling of EGF to the fl uorophore 
did not affect receptor affi nity. 
To confi rm that bioactivity of the targeting agent was in-
dicated accurately by binding affi nity, we used an In-Cell 
Western assay that was developed previously for the quan-
tifi cation of kinase phosphorylation in whole cells [24]. No 
signifi cant decrease in ERK phosphorylation was noted be-
tween cells treated with equimolar concentrations of unla-
beled EGF and IRDye 800CW EGF (data not shown). This 
is consistent with results from other investigators who have 
shown that both fl uorescein isothiocyanate (FITC)–EGF [7] 
and fl uorescent quantum dot–EGF [28] conjugates are ef-
fectively internalized by ligand-induced endocytosis of the 
bound EGF receptor complex, also a downstream effect of 
biologically intact EGF.
Impairment of binding of EGF and EGF-stimulated ERK 
phosphorylation by HPLC purifi cation
We next evaluated whether the microplate binding and
 In-Cell Western assays could effectively distinguish between 
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ligands with differential binding affi nities. To obtain low-af-
fi nity ligands for comparisons, we conjugated IRDye 800CW 
to EGF from four independent commercial sources and sub-
jected each conjugate to HPLC purifi cation. Binding of these 
four targeting agents (denoted A, B, C, and D in Figure 2) to 
A431 cells was compared by NIR fl uorescence intensity to 
the binding of standard maximally active FPLC-purifi ed con-
jugate from sources A and B. All four preparations demon-
strated signifi cant reductions in binding (up to 60%) at all con-
centrations (Figure 2A). Thus, the damage infl icted on EGF 
by HPLC treatment dramatically affected its cell binding po-
tential. When we assayed p-ERK levels using the four tar-
geting agents compared with unlabeled (data not shown) or 
conjugated EGF from sources A and B (Figure 2B), the best 
performance of any HPLC-purifi ed compound was 28% of 
unlabeled EGF stimulation. Reduced levels of ERK phos-
phorylation confi rmed compromised function of the HPLC-
treated targeting agents. 
Kinetics of IRDye 800CW EGF clearance in vivo
Ultimately, our goal was to determine whether impaired 
function of the EGF receptor targeting agent in vitro would 
correlate with poor tumor targeting in mice. We fi rst deter-
mined clearance kinetics of the targeting agent in normal 
and tumor-bearing mice. Clearance was monitored by inject-
ing animals with 1 nmol of FPLC-purifi ed IRDye 800CW 
EGF via the tail vein and collecting NIR images over time 
from 15 min to 24 h (Figure 3A). The pseudo-colored im-
ages depict the color-enhanced fl uorescence intensity super-
imposed on white light images of a representative mouse. 
Fluorescence intensity in regions of interest encompassing 
the whole animal (large ROI) or limited to the abdominal 
area (small ROI) was quantifi ed to evaluate clearance. We 
Figure 1. In vitro binding specifi city of IRDye 800CW EGF for tu-
mor cells in culture. A431 cells cultured to 90% confl uence in 96-
well plates were incubated with increasing concentrations of IRDye 
800CW EGF (diamonds) or unconjugated nonreactive IRDye 800CW 
(circles) for 2 min and then washed, fi xed, permeabilized, and stained 
with TO-PRO-3 (A). For competitions, cells were incubated with a 
fi xed concentration of IRDye 800CW EGF (70 nM) containing the 
indicated concentrations of unlabeled EGF (B) or C225, an EGF re-
ceptor blocking antibody (C). All plates were scanned at two wave-
lengths on the Aerius near-infrared scanner. The 800-nm signal, nor-
malized to the 700-nm control, is plotted as the means ± SD of three 
replicate wells. 
Figure 2. Biological activity elicited by labeled EGF. EGF from 
four sources (denoted as A, B, C, and D) was conjugated to IRDye 
800CW and purifi ed by HPLC. A431 cells at 90% confl uence in 96-
well plates were stimulated with the indicated concentrations of the 
respective agents or with the maximally active FPLC-purifi ed con-
jugates corresponding to sources A and B. The plate was scanned to 
quantify binding of the IRDye 800CW EGF targeting agents (A). 
The extent of ERK phosphorylation stimulated in each condition was 
assessed in the same plate by the In-Cell Western assay using anti-
bodies to total ERK and p-ERK (B). The mean ± SD for three repli-
cate wells is plotted. 
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observed an initial increase in whole animal fl uorescence in-
tensity for the fi rst 3 to 4 h as the targeting agent circulated 
to the capillaries of the skin. Subsequently, the signal was 
seen to pass through the liver, intestines, kidneys, and blad-
der. The analysis confi rmed that 75% of the signal cleared 
after 8 h and that more than 90% cleared after 24 h. 
Then we monitored a similar time course for clearance of 
the targeting agent from tumor-positive animals (Figure 3B). 
Mice bearing subcutaneous tumors of approximately 0.5 cm 
in diameter (measured by digital calipers) were injected as 
above with IRDye 800CW EGF, imaged immediately, and 
imaged repeatedly at 24-h intervals. As observed for the tu-
mor-negative controls, whole animal and abdominal signal 
intensity peaked at 3 to 4 h but had diminished by more than 
90% within 24 h (data not shown). Analysis of SNR compar-
ing mean fl uorescence intensity in an arbitrarily chosen ROI 
within the tumor, designated as a blue ellipse, to the mean of 
four background areas of identical size, shown as orange el-
lipses, exhibited an initial time-dependent increase. Eventual 
saturation of SNR indicated that the time of maximal sensitiv-
ity for imaging was 72 to 96 h, and subsequent images were 
collected at 72 h (Figure 3B). In vivo, IRDye 800CW EGF 
fl uorescence following systemic clearance was amplifi ed in 
the tumors relative to the whole animals and was also specifi c, 
Figure 3. Clearance kinetics of IRDye 800CW EGF from normal and tumor-bearing mice. (A) IRDye 800CW EGF (1 nmol) was injected in-
travenously into a normal NOD/SCID mouse. Images were collected prior to injection (0 h) and at the indicated times postinjection. Results are 
shown as color-enhanced fl uorescence intensity superimposed on the white light images in the ventral view. Signal intensities (at 789 nm) were 
normalized to background fl uorescence and plotted using the whole animal (large ROI, dark bars) or an arbitrary abdominal ellipse (small ROI, 
light bars) as ROIs. (B) IRDye 800CW EGF was injected intravenously into mice with subcutaneous PC3M-LN4 prostate tumor xenografts, 
and images were collected at the indicated times postinjection. SNR was calculated using a single elliptical ROI denoted on the tumor in blue 
and four background ellipses (orange) placed arbitrarily in irrelevant adjacent sites on the fl ank as shown. Fluorescence is also present in the 
kidneys in these dorsal views. Calculated SNR was plotted to obtain an optimal imaging time point for subsequent experiments. 
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as shown by antibody blocking. The sensitivity of this fl uo-
rescence signal lends support to the choice of EGF receptor 
as an epithelial or prostate tumor target and demonstrates that 
IRDye 800CW is an effective labeling fl uorophore.
Subcutaneous tumor targeting by IRDye 800CW EGF
To optimize targeting and tumor-specifi c signal accumula-
tion in noninvasive imaging, it is important to understand 
the functional parameters of the biomarker and its response 
to the target. Using the In-Cell Western assay, we detected 
impaired binding and response of the EGF receptor sig-
naling cascade when the EGF conjugate was subjected to 
HPLC treatment. We performed an animal imaging study to 
determine whether impaired binding function would trans-
late to poor tumor signal. FPLC- or HPLC-purifi ed IRDye 
800CW EGF from two sources (A and B) was injected via 
the tail vein into athymic mice bearing approximately 0.5-
cm subcutaneous A431 tumors. Mice were imaged 3 days 
postinjection (Figure 4). The arrowheads in Figure 4 indi-
cate positions of detected tumor tissue in these representa-
tive fl uorescence images, which have been corrected for 
background. Figs. 4A and C illustrate signal intensity in an-
imals injected with the FPLC-purifi ed targeting agent, and 
Figs. 4B and D show the effect of the corresponding HPLC 
form. These images were analyzed to determine total fl uo-
rescence in the tumor (Table 1). Mice receiving HPLC-puri-
fi ed targeting agents from the two different preparations had 
approximately 28 and 64% lower signal compared with mice 
injected with minimally damaged agents (Table 1). Similar 
results were obtained when damaged agents were injected 
in mice bearing 22Rv1 prostate tumors, confi rming that this 
phenomenon is not unique to the A431 cells. In images not 
shown, additional mice were injected with HPLC-purifi ed 
probes from sources C and D, but the fl uorescence signal 
from these animals was diminished 80 to 90% with respect 
to that calculated for the animals receiving optimized prepa-
rations (Table 1). Thus, the magnitude of the differences var-
ied considerably, but a targeting agent exhibiting suboptimal 
signaling potential in vitro correlated strongly with poor sig-
nal strength in live animal imaging. 
Finally, tumors were excised and sectioned for fl uores-
cence scanning analysis to verify whether signal intensity 
measured in the animal was attributable to fl uorescence in the 
tumor tissue and whether the intensity was consistent through-
out the tumor. Sections were scanned on the Odyssey in two 
channels, and the corresponding merged images are shown as 
insets in Figure 4. Red represents tissue autofl uorescence in 
the 700-nm channel, and green denotes specifi c fl uorescence 
in the 800-nm channel resulting from IRDye 800CW EGF. 
Normalized fl uorescence of the tissue sections is presented in 
Table 1. Signal intensity was evident throughout the tumors 
irrespective of targeting agent. Consistent with results from 
intact animal image analysis, sections exhibited signal reduc-
tions of approximately 25 to 60%. Thus, performance of tar-
geting agents damaged by HPLC purifi cation, as identifi ed in 
vitro by the assay for ERK phosphorylation, again translated 
to poor outcomes in whole animal imaging experiments.
In conclusion, we have characterized an effective target-
ing agent for noninvasive optical detection and tracking of 
tumors in mice. The fl uorophore used, IRDye 800CW, can 
be easily coupled to many ligand or targeting molecules of 
interest. We have found that an in vitro assay that detects 
binding and effi cacy of EGF-conjugated products in stim-
ulating downstream biological function is an accurate esti-
mate of targeting effi cacy in vivo. We expect this applica-
tion to have further value in probe and drug development as 
a correlate assay for other biolabels to estimate competitive 
ligand and/or drug interactions in vivo. 
Figure 4. Targeting agent quality analysis in vivo. Male athymic Nu/
Nu mice bearing A431 subcutaneous tumors (~0.5 cm diameter) were 
injected intravenously with IRDye 800CW EGF (1 nmol) purifi ed by 
FPLC (A and C) or HPLC (B and D). Panels A and B illustrate use 
of the conjugate to EGF from source A in Figure 3, and for panels C 
and D source B was used. Images were collected on anesthetized an-
imals at 72 h postinjection. Tumors were excised, fi xed, paraffi n em-
bedded, and sectioned for fl uorescence signal determination by two-
color scanning on the Odyssey (inset panels). 
Table 1.  Summary of tumor imaging results 
a Normalized fl uorescence for intact animals: mean pixel fl uorescence (tumor) 
minus mean pixel fl uorescence (background).
b 800 nm fl uorescence per area (mm2).
c Comparison with source A FPLC to determine percentage loss.
d Comparison with source B FPLC to determine percentage loss (numbers in 
parentheses).
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